CRP is associated with reduced endothelial vasoreactivity, and pharmacologic lowering of this marker could possibly reduce endothelial dysfunction, a process implicated in aneurysm development and rupture [27,63]. The gene discussed is CRP; the disease is endothelial dysfunction.